Microbix Biosystems IncTSX:MBXView on OTCQX International
- LAST PRICE0.3000
- TODAY'S CHANGE (%)-0.0100 (-3.2258%)
- Bid / Lots0.3000/ 30
- Ask / Lots0.3150/ 35
- Open / Previous Close0.3050 / 0.3100
- Day Range
- 52 Week Range
- Volume121,086
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MBX |
|---|---|---|
| 09:32 ET | 2000 | 0.305 |
| 10:26 ET | 3000 | 0.315 |
| 10:27 ET | 500 | 0.31 |
| 10:44 ET | 8000 | 0.31 |
| 11:18 ET | 4000 | 0.31 |
| 11:43 ET | 4500 | 0.315 |
| 03:42 ET | 6500 | 0.31 |
| 03:44 ET | 59500 | 0.3 |
| 03:57 ET | 32500 | 0.3 |
Nov 12, 2024
KOL Collaborators Present Microbix HPV Test-Control Results, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Microbix Biosystems Inc | 42.0M | 8.1x | --- |
Avicanna Inc | 27.9M | -3.7x | --- |
COSCIENS Biopharma Inc | 15.5M | -0.4x | --- |
Medicure Inc | 9.2M | -3.5x | --- |
Numinus Wellness Inc | 12.9M | -0.6x | --- |
Briacell Therapeutics Corp | 30.5M | -2.5x | --- |
Company Information
Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.
Contact Information
- Headquarters
- 265 Watline AvenueMISSISSAUGA, ON, Canada L4Z 1P3
- Phone
- 905-361-8910
- Fax
- 905-361-8910
Executives
- Independent Chairman of the Board
- Martin Marino
- President, Chief Executive Officer, Director
- Cameron Groome
- Chief Financial Officer
- James Currie
- Chief Operating Officer
- Kenneth Hughes
- Senior Vice President - Sales and Business Development
- Phillip Casselli
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $40.7M |
|---|---|
Revenue (TTM) | $23.4M |
Shares Outstanding | 135.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.34 |
EPS | $0.04 |
Book Value | $0.18 |
P/E Ratio | 8.1x |
Price/Sales (TTM) | 1.7 |
Price/Cash Flow (TTM) | 6.2x |
Operating Margin | 21.73% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
